{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:28:57Z","timestamp":1745494137385},"reference-count":23,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1111\/tbj.12571","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T11:58:10Z","timestamp":1455191890000},"page":"293-302","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity"],"prefix":"10.1155","volume":"22","author":[{"given":"Juan","family":"Bayo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology; Hospital Juan Ram\u00f3n Jim\u00e9nez; Huelva Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Prieto","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department; Hospital Juan Ram\u00f3n Jim\u00e9nez; Huelva Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Experimental Psychology; Universidad de Sevilla; Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"10.1111\/tbj.12571-BIB0001|tbj12571-cit-0001","unstructured":"Howlader N Noone AM Krapcho M et al SEER Cancer Statistics Review, 1975-2011 Bethesda, MD National Cancer Institute 2014 http:\/\/seer.cancer.gov\/csr\/1975_2011\/"},{"key":"10.1111\/tbj.12571-BIB0002|tbj12571-cit-0002","unstructured":"Ferlay J Soerjomataram I Ervik M et al GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France International Agency for Research on Cancer 2013 http:\/\/globocan.iarc.fr\/Default.aspx"},{"key":"10.1111\/tbj.12571-BIB0003|tbj12571-cit-0003","first-page":"231","article-title":"Epidemiological situation of breast cancer in Spain [Spanish]","volume":"4","author":"Poll\u00e1n","year":"2007","journal-title":"Psicooncolog\u00eda"},{"key":"10.1111\/tbj.12571-BIB0004|tbj12571-cit-0004","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.medcli.2013.09.042","article-title":"[Proportion of breast cancer in women aged 50 to 69 years from Girona, Spain, according to detection method]","volume":"143","author":"Puig-Vives","year":"2014","journal-title":"Med Cl\u00ednica"},{"key":"10.1111\/tbj.12571-BIB0005|tbj12571-cit-0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ejca.2008.11.003","article-title":"The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis","volume":"45","author":"De Angelis","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1111\/tbj.12571-BIB0006|tbj12571-cit-0006","unstructured":"GEICAM (Grupo Espa\u00f1ol de Investigaci\u00f3n en C\u00e1ncer de Mama) Avda de los Pirineos, 7 Oficina 1-14. San Sebasti\u00e1n de los Reyes 28703 Madrid. Impreso en Madrid"},{"key":"10.1111\/tbj.12571-BIB0007|tbj12571-cit-0007","unstructured":"National Institute for Health and Care Excellence Advanced breast cancer (update) Diagnosis and treatment https:\/\/www.nice.org.uk\/guidance\/cg81\/resources\/guidance-advanced-breast-cancer-update-pdf"},{"key":"10.1111\/tbj.12571-BIB0008|tbj12571-cit-0008","unstructured":"National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Breast cancer 2012 http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"10.1111\/tbj.12571-BIB0009|tbj12571-cit-0009","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12571-BIB0010|tbj12571-cit-0010","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Mart\u00edn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12571-BIB0011|tbj12571-cit-0011","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMe058056","article-title":"TAC-a new standard in adjuvant therapy for breast cancer?","volume":"352","author":"Perez","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12571-BIB0012|tbj12571-cit-0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1111\/tbj.12571-BIB0013|tbj12571-cit-0013","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.1991.9.12.2148","article-title":"A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer","volume":"9","author":"Perez","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12571-BIB0014|tbj12571-cit-0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12094-009-0344-8","article-title":"Epidemiologic study to assess patient involvement in choice of adjuvant chemotherapy for breast cancer (PROSA Study)","volume":"11","author":"Tusquets","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"10.1111\/tbj.12571-BIB0015|tbj12571-cit-0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.10630","article-title":"Changing patient perceptions of the side effects of cancer chemotherapy","volume":"95","author":"Carelle","year":"2002","journal-title":"Cancer"},{"key":"10.1111\/tbj.12571-BIB0016|tbj12571-cit-0016","unstructured":"Common Terminology Criteria for Adverse Events v3.0 2003 http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"issue":"Suppl 1","key":"10.1111\/tbj.12571-BIB0017|tbj12571-cit-0017","first-page":"79","article-title":"[The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]","volume":"112","author":"Badia","year":"1999","journal-title":"Med Cl\u00ednica"},{"key":"10.1111\/tbj.12571-BIB0018|tbj12571-cit-0018","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/tbj.12571-BIB0019|tbj12571-cit-0019","volume-title":"Calidad de vida en pacientes intervenidas de c\u00e1ncer de mama","author":"Royo Aznar","year":"2012"},{"key":"10.1111\/tbj.12571-BIB0020|tbj12571-cit-0020","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1200\/JCO.2011.38.7605","article-title":"Quality of breast cancer care: perception versus practice","volume":"30","author":"Bickell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12571-BIB0021|tbj12571-cit-0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","article-title":"Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives","volume":"10","author":"Salsman","year":"2012","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1111\/tbj.12571-BIB0022|tbj12571-cit-0022","doi-asserted-by":"crossref","first-page":"e2718","DOI":"10.1136\/bmj.e2718","article-title":"Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13,722 women","volume":"344","author":"Kesson","year":"2012","journal-title":"BMJ"},{"key":"10.1111\/tbj.12571-BIB0023|tbj12571-cit-0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.12571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tbj.12571\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:28:19Z","timestamp":1643351299000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.12571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1111\/tbj.12571","archive":["Portico"],"relation":{},"ISSN":["1075-122X"],"issn-type":[{"value":"1075-122X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2,11]]}}}